59% vs raltegravir 58%; treatment diff erence 1·1%,
95% CI –6·0 to 8·2), and elvitegravir met the prespecifi ed
criterion for non-inferiority. Side-eff ects were generally
mild and comparable between arms, except for a
signifi cantly higher frequency of grade 3 or 4 rises
in alanine aminotransferase concentrations in the
raltegravir arm (p=0·020) and an excess of diarrhoea in
the elvitegravir arm (p=0·023).